Vitravene Preservative Free

(Fomivirsen sodium)

Phase 2Small molecule

Vitravene Preservative Free is one of 10 small molecule programs targeting Cytomegalovirus Retinitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cytomegalovirus RetinitisActive, not recruiting

Cytomegalovirus RetinitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Cytomegalovirus Retinitis

#DrugCompanyPhaseTrials

Cytovene

EExela Pharma Sciences, LLC.

Phase 3

7 2

Leukine

Vistide

2 4

Viracept

AAgouron Pharmaceuticals

Phase 2

1 5

Foscavir

CClinigen, Inc.

Phase 3

1 6

Vitravene Preservative Free

Novartis

Phase 2

2 7

Retrovir

BBp Consulting, Inc

Preclinical

2 8

Benemid

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Zovirax

BBp Consulting, Inc

Preclinical

1 10

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cytomegalovirus Retinitis2 trials

A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·N/A·NCT00002187

A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 2·NCT00002156·194 enrolled

Cytomegalovirus (CMV)2 trials

A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·N/A·NCT00002355·60 enrolled

The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 2·NCT00002356

Regulatory

FDA Approval Timeline[4]

Aug 26, 1998

VITRAVENE PRESERVATIVE FREE

NDA NDA020961

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Fomivirsen sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fomivirsen sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fomivirsen sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020961). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Vitravene Preservative Free

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cytomegalovirus Retinitis2 trials

Cytomegalovirus (CMV)2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News